A group of companies are making special cars that run on electricity instead of gasoline. The people who buy these cars need a place to charge them, so the government is helping some companies build charging stations. One company from China got a big contract to make some of these stations. Some other companies saw their stock prices go up because they think they can also get contracts or sell more products. A few companies had problems and their stock prices went down because they might have trouble paying their bills or need help from the government to stay in business. Read from source...

1. The title of the article is misleading and clickbait, as it suggests that 4D Molecular Therapeutics is the main reason for the stock market movements, while in reality, it is only one of many factors influencing the premarket trading. A more accurate title would be something like "Various Factors Impacting Pre-Market Trading; 4D Molecular Therapeutics Among Them".
2. The article does not provide any evidence or data to support the claim that 4D Molecular Therapeutics shares are trading higher by 20%. This is a significant increase and should be backed up by reliable sources or charts, but the article lacks such information.
3. The section on YanGuFang International Group Co., Ltd. contains a grammatical error ("YanGuFang" instead of "YanGuFang International") and an inconsistency in the percentage gain (27.4% vs $0.7641). This shows poor editing and fact-checking by the authors.
4. The article does not explain why some stocks are moving premarket, which would be helpful for readers who want to understand the market trends and potential reasons behind them. For example, why did CalAmp Corp.'s shares gain 16.8% after announcing a reverse stock split? What is the significance of this move for the company and its investors?
5. The article mentions several companies that filed for bankruptcy or received delisting notices (DMK Pharmaceuticals, NanoString Technologies, Bit Brother Limited), but does not discuss their implications for the market or the reasons behind their financial struggles. This is an important aspect of the premarket trading story that should be explored and explained to readers.
6. The article ends with a paragraph about NexImmune announcing a registered direct offering, which seems unrelated to the main topic of the article (premarket trading). Why did the authors include this information, and what is its relevance to 4D Molecular Therapeutics or other stocks mentioned in the article?
7. The overall tone of the article is sensationalist and emotional, rather than informative and rational. It tries to create a sense of urgency and excitement by using words like "higher", "trading", "moving", "here are 20 stocks", etc., but does not provide any solid information or analysis for readers to base their decisions on. This is irresponsible journalism that could potentially mislead investors or cause unnecessary panic in the market.

1. YanGuFang International Group Co., Ltd. (YGF) - Buy with high risk, potential for significant gains if the company successfully launches its new products and expands its market share in China and abroad. The stock is highly volatile and may experience sharp swings based on news and announcements from the company or regulators.
2. Magic Empire Global Limited (MEG) - Sell with high risk, the stock has no fundamentals to support its valuation and appears to be a speculative bubble fueled by social media hype and celebrity endorsements. The stock may collapse if investor interest fades or if the company fails to deliver on its promises of revolutionizing digital entertainment.
3. CalAmp Corp. (CALM) - Hold with medium risk, the stock has fallen significantly after announcing a reverse stock split and may present an attractive entry point for long-term investors who believe in the company's growth prospects in IoT solutions and software-as-a-service. The stock is subject to market fluctuations and may benefit from positive news or developments in the industry.
4. Cadrenal Therapeutics, Inc. (CDTX) - Buy with high risk, the stock has soared on optimism about its Phase 3 trial results for lead product candidate CRT-201 in patients with vasomotor symptoms associated with menopause. The stock may see further gains if the data is positive and supports the safety and efficacy of the drug, but it also faces significant uncertainty and competition from other treatments.
5. Atara Biotherapeutics, Inc. (ATRA) - Buy with high risk, the stock has rallied on reports of a takeover bid by a third party, which may or may not materialize. The company is developing innovative therapies for cancer and other serious diseases, but also faces risks from clinical trials, regulatory approvals, and competition.
6. Griid Infrastructure Inc. (GRDI) - Buy with high risk, the stock has rebounded sharply after a steep decline due to concerns about its exposure to crypto currency-related assets. The company is a leading digital infrastructure provider for the blockchain ecosystem and may benefit from increasing adoption and demand for crypto currencies and other decentralized applications.
7. Cano Health, Inc. (CANO) - Sell with high risk, the stock has plunged after announcing its Chapter 11 bankruptcy filing, which may result in a loss of value or even complete dilution for shareholders. The company is facing financial and operational challenges due to its complex and cost